SALT LAKE CITY and FREMONT, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc., a leader in advanced genomics for precision oncology, (Nasdaq: PSNL) today announced a non-exclusive collaboration through which Myriad will market the Personalis®…Read More
Myriad Genetics Inc Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
